Julie Hambleton - 25 Jul 2024 Form 4 Insider Report for IGM Biosciences, Inc. (IGMS)

Role
Director
Signature
/s/ Misbah Tahir, by power of attorney
Issuer symbol
IGMS
Transactions as of
25 Jul 2024
Net transactions value
-$190,815
Form type
4
Filing time
29 Jul 2024, 17:45:15 UTC
Previous filing
21 Jun 2024
Next filing
12 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IGMS Common Stock Options Exercise $21,033 +15,132 +757% $1.39 17,132 25 Jul 2024 Direct F1
transaction IGMS Common Stock Sale $211,848 -15,132 -88% $14.00 2,000 25 Jul 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IGMS Stock Option (right to buy) Options Exercise $0 -15,132 -100% $0.000000* 0 25 Jul 2024 Common Stock 15,132 $1.39 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2024.
F2 All of the shares subject to this option are fully vested and exercisable as of the date hereof.